LXCHEM Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹719 Cr
verified against source
Revenue YoY
-9%
reported change
EBITDA
₹50 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laxmi Organic Industries reported a challenging Q3 FY26 with revenue declining ~9% YoY, EBITDA at ~₹50 crore (-33% YoY), and PAT at ₹25 crore (-15% YoY). The specialty segment bore the brunt with 30% revenue decline—driven by 12% price moderation, 10% from an agrochemical intermediate phase-out, and 5-6% from a non-recurring campaign product. Essential segment volumes held flat though revenue fell 6% due to lower acetic acid feedstock prices. Management sees green shoots with acetic acid prices rebounding from ~$320-330 to ~$360, pushing ethylacetate spreads from $90-100 toward $130 range. The ₹710 crore Dahej capex (Phase 2 completion targeted Q4 FY26) will drive FY27 specialty ramp-up, while Phase 1 is already supplying customers. Fluoro intermediates remain on track toward ~₹70-80 crore revenue target. The global chemical landscape remains challenging with continued restructuring, but India demand remains a relative positive outlier. Key risks include sustained acetic acid price volatility, customer concentration at the Dahej facility, and margin pressure from new facility costs while volumes ramp.
Colored figures show movement against the previous available record.
Guidance to track
- Mechanical completion of the ₹710 crore Dahej facility targeted by end of Q4 FY26, with FY27 being the first year of customer qualification and volume ramp-up.
- Laxmi's fluoro intermediates operation targeting ~₹70-80 crore revenue run-rate in FY26, with FY28 expected for accelerated ramp-up.
- Current focus on volume-driven profitable growth in both specialties and essentials, with 70% of essentials business domestic where India demand remains a positive outlier versus global peers.
Risks flagged
- Despite recent rebound to $360, Chinese New Year could see capacities come back online and pressure prices. Management expects $330-380 range but acknowledged uncertainty post-holiday period.
- The Dahej specialty investment is linked to a multi-year contract with one customer who is simultaneously ramping up their downstream facility. Management declined to disclose current volumes citing customer confidentiality.
- Q3 specialty EBITDA margins were 12-13%, well below historical 20-25% range. Management avoided confirming Q3 was the trough, stating 'we will have to navigate it quarter on quarter' and only committed to FY28 for meaningful improvement.
- When feedstocks decline, specialty product pricing cannot remain insulated despite the 'specialty' classification. This interconnectedness between commodity and specialty pricing was acknowledged as an ongoing headwind.
Key quotes
- While yes on the capacity supply demand dynamics it is long but at these price points you are also seeing it is not sustainable to operate despite the fact you have capacity.
- I think we will have to navigate it quarter on quarter. Chemicals is challenging. I do not want to wish that away. At least on the upstream feed stock lens we certainly see that things seems to be rebounding but I would still take it quarter on quarter.
- FY27 would be the first year of qualification plus ramp up and FY28 is where we will try to further fast-track the ramp up.
Research modules